Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349101 · ClinicalTrials.gov registry record · Phase 2
A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT01349101 is a Phase 2 study that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 78 participants.
The verdict
NCT01349101, a Phase 2 study, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of cyclophosphamide post stem cell infusion with alternative donors will be as safe and as effective as traditional matched transplants.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Tacrolimus
- RADIATION Total Body Irradiation
- DRUG Mycophenolate mofetil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2011-02-10 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01349101
The ClinicalTrials.gov registry entry for NCT01349101 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT01349101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01349101 about?
NCT01349101 is a clinical study titled "A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors". It is hypothesized that engraftment when administering cyclophosphamide post the stem cell infusion will increase, the incidence of graft versus host disease (GVHD) and day 100 mortality will decrease, and the use of cyclophosphamide post stem cell infusion with alternative donors will be as safe an...
What is the current status of trial NCT01349101?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2011-02-10. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT01349101?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Tacrolimus (DRUG), Total Body Irradiation (RADIATION), Mycophenolate mofetil (DRUG).
Who is sponsoring clinical trial NCT01349101?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.